This project will uncover genetic pathways and FDA approved drugs that have novel anti-tumor activity in a rare, pediatric malignancy of muscle -- embryonal rhabdomyosarcoma (ERMS). Rhabdomyosarcoma effects over 250 patients annually in the United States, of which ERMS is the most common subtype. Our work has already identified a key genetic pathway involved in ERMS tumor growth, the RAS pathway.
Fighting childhood cancer, one cup at a time.
